Retatrutide

What it is

Retatrutide is an experimental peptide that acts as a triple agonist: it acts on the receptors for GLP-1, GIP and glucagon. It was developed in pharmaceutical research and appears in the scientific literature under the research code LY3437943.

Mechanism of action

Each of the three receptors retatrutide acts on plays a role in regulating blood glucose and energy metabolism. Acting on all three at once distinguishes it pharmacologically from substances that act on one or two of them. This describes the point of action, not a guaranteed effect.

Research status

Retatrutide has been studied in clinical trials in humans, including phase 2, and is being followed in further research. That is a considerably later stage than substances examined only in animal studies — but it is emphatically not a completed registration process. While that process is ongoing, efficacy and safety outside the controlled trial setting are not established.

Regulatory status

Retatrutide is not approved by the EMA, the FDA or the CBG. There is no marketing authorisation; it is not a medicine. Material offered online falls outside all pharmaceutical supervision.

What remains unknown

Long-term safety, effects outside trial conditions and interactions are insufficiently known. For unregulated material, uncertainty about composition and purity is added on top — see Quality & provenance.